Abstract
The fungistatic and fungicidal activities of sertaconazole against dermatophytes were evaluated by testing 150 clinical isolates of causative agents of tinea pedis, Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. The overall geometric means for fungistatic and fungicidal activities of sertaconazole against these isolates were 0.26 and 2.26 μg/ml, respectively, although values were higher for T. mentagrophytes than for the others. This is the first comprehensive demonstration of the fungicidal activity of sertaconazole against dermatophytes.
TEXT
Dermatophytes are a subgroup of fungi that can invade keratinized tissue in mammals and fowl and subsequently cause an infection (26). Tinea pedis, also known as athlete's foot, is caused predominately by Trichophyton rubrum, followed by Trichophyton mentagrophytes and Epidermophyton floccosum (1, 26). In fact, T. rubrum and T. mentagrophytes are the most common dermatophytes in the United States, Europe, and Asia (1). There are an estimated 750,000 outpatient visits annually for tinea pedis in the United States (21), and its prevalence has been increasing in developed countries over the last several decades (1).
Treatment options for tinea pedis include topical antifungal creams and, in severe cases, oral antifungals (23, 26). The fungistatic activity of the topical azole derivative sertaconazole nitrate, (±)-1-[2,4-dichloro-β-[(7-chlorobenzo[b]thien-3yl)methoxy]phenethyl]imidazole nitrate, against dermatophytes has been previously described (3–6, 10), but the only available fungicidal data against dermatophytes are limited to two strains of T. mentagrophytes (13). Sertaconazole has previously been shown to exhibit both fungistatic and fungicidal activities against several Candida species and other yeasts (2, 7–9, 11, 13, 17–20).
In this study, the susceptibilities of 150 isolates of T. rubrum, T. mentagrophytes, and E. floccosum to sertaconazole were tested by using a previously described, standardized broth microdilution method (3, 4, 14), which was adapted from the Clinical and Laboratory Standards Institute (CLSI) document M38-A for opportunistic filamentous fungi (12). Prior to the antifungal susceptibility testing, isolates were subcultured on antimicrobial agent-free potato dextrose agar (Biolife Italiana, Milan, Italy) at 28°C for 7 to 15 days and reverified by morphological (macro- and microscopic) and biochemical methods. Briefly, inocula were prepared and diluted in RPMI 1640 medium with l-glutamine and without sodium bicarbonate (Sigma-Aldrich, St. Louis, MO) buffered at pH 7.0 with 0.165 M morpholinepropanesulfonic acid (Sigma-Aldrich, St. Louis, MO) as previously described (3, 4, 14). Sertaconazole nitrate (Grupo Ferrer, Barcelona, Spain) was dissolved to 1,600 mg/ml in 100% dimethyl sulfoxide. Aliquots of sertaconazole (final concentrations ranging from 0.016 to 16 μg/ml) and inocula (final densities ranging from 4.7 × 103 to 1.5 × 104 CFU/ml, as recommended [12]) were combined in sterile, round-bottom, 96-well microdilution plates (Soria-Greiner, Madrid, Spain), incubated at 28°C, and observed for the presence or absence of visible growth. Microdilution wells were scored as follows by visual measurements at 5 days or until development of growth in the control wells: 0, optically clear; 1, slightly hazy; 2, prominent decrease in turbidity; 3, slight reduction in turbidity; 4, no reduction of turbidity. The MIC was determined as the lowest concentration with a score of 2. Aspergillus fumigatus strains NCPF 7100 and NCPF 7099 were tested as controls in each antifungal susceptibility batch. Minimal fungicidal concentrations (MFC) were determined by subculturing volumes of 10 μl from wells with a score of 0, spreading onto Sabouraud agar plates, and evaluating growth after 5 days at 28°C (22).
Sertaconazole was fungistatic against all three species of dermatophytes tested, with an overall geometric mean MIC of 0.26 μg/ml (Table 1). Sertaconazole was more active against E. floccosum and T. rubrum than against T. mentagrophytes (geometric mean MIC values of 0.12, 0.19, and 0.73 μg/ml, respectively). These trends are consistent with two previous studies that, using this method, found respective geometric mean MIC values of 0.07 and 0.08 μg/ml for E. floccosum, 0.19 and 0.13 μg/ml for T. rubrum, and 0.62 and 0.49 μg/ml for T. mentagrophytes (3, 4).
Table 1.
Dermatophyte (n) | MIC data (μg/ml) |
MFC data (μg/ml) |
|||||
---|---|---|---|---|---|---|---|
GMa | Range | MIC50 | MIC90 | GMa | MFC50 | MFC90 | |
Trichophyton rubrum (100) | 0.19 | 0.02–16 | 0.25 | 1 | 1.78 | 4 | ≥16 |
Trichophyton mentagrophytes (40) | 0.73 | 0.02–16 | 1 | 8 | 4.76 | 8 | ≥16 |
Epidermophyton floccosum (10) | 0.12 | 0.02–16 | 0.06 | 0.5 | 1.23 | 1 | 8 |
All isolates (150) | 0.26 | 0.02–16 | 0.25 | 2 | 2.26 | 4 | ≥16 |
GM, geometric mean.
The results of this study also demonstrate the fungicidal activity of sertaconazole against the dermatophytes tested, with a geometric mean MFC value of 2.26 μg/ml (Table 1). This value differs from the MFC values of ≥50 μg/ml previously reported for two strains of T. mentagrophytes, although it should be noted that this study utilized a different methodology (13). When the inhibition curves were compared, statistically significant differences (P < 0.05; Student's t test) were found between the concentrations of sertaconazole necessary for fungistatic and fungicidal activities (Fig. 1). The concentrations of sertaconazole needed to achieve either fungistatic or fungicidal activity were far below those reached after topical application (15). Nevertheless, the clinical advantage of fungicidal over fungistatic agents remains unclear, based on a recent examination of antifungal agents (16).
In conclusion, data obtained with 150 clinical isolates of the dermatophytes T. rubrum, T. mentagrophytes, and E. floccosum, causative agents of tinea pedis, demonstrated that sertaconazole exhibits a fungicidal and fungistatic profile, with greater activities against T. rubrum and E. floccosum than against T. mentagrophytes. These dual fungicidal and fungistatic activities of sertaconazole are consistent with its efficacy against tinea pedis in randomized, placebo-controlled clinical trials (24, 25).
Acknowledgments
We thank Ana Espinel-Ingroff (Virginia Commonwealth University) for critical reading of the manuscript. Jennifer L. Giel of Evidence Scientific Solutions, Philadelphia, PA, provided editorial support, which was funded by Johnson & Johnson.
Footnotes
Published ahead of print on 11 July 2011.
REFERENCES
- 1. Ameen M. 2010. Epidemiology of superficial fungal infections. Clin. Dermatol. 28:197–201 [DOI] [PubMed] [Google Scholar]
- 2. Carrillo-Muñoz A. J., et al. 2001. Sertaconazole: in-vitro antifungal activity against vaginal and other superficial yeast isolates. J. Chemother. 13:555–562 [DOI] [PubMed] [Google Scholar]
- 3. Carrillo-Muñoz A. J., Fernandez-Torres B., Cardenes D. C., Guarro J. 2003. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility. Chemotherapy 49:248–251 [DOI] [PubMed] [Google Scholar]
- 4. Carrillo-Muñoz A. J., Fernandez-Torres B., Guarro J. 2003. In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates. J. Chemother. 15:555–557 [DOI] [PubMed] [Google Scholar]
- 5. Carrillo-Muñoz A. J., et al. 2004. In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis. Chemotherapy 50:308–313 [DOI] [PubMed] [Google Scholar]
- 6. Carrillo-Muñoz A. J., et al. 2008. In vitro antifungal activity of sertaconazole nitrate against recent isolates of onychomycosis causative agents. J. Chemother. 20:521–523 [DOI] [PubMed] [Google Scholar]
- 7. Carrillo-Muñoz A. J., Torres-Rodriguez J. M. 1995. In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. J. Antimicrob. Chemother. 36:713–716 [DOI] [PubMed] [Google Scholar]
- 8. Carrillo-Muñoz A. J., Tur-Tur C. 1997. Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. Chemotherapy 43:387–392 [DOI] [PubMed] [Google Scholar]
- 9. Carrillo-Muñoz A. J., Tur-Tur C., Bornay-Llinares F. J., Arevalo P. 1999. Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J. Chemother. 11:187–190 [DOI] [PubMed] [Google Scholar]
- 10. Carrillo-Muñoz A. J., Tur C., Estivill D., Torres J. 1995. In vitro activity of sertaconazole and bifonazole against dermatophytes. J. Mycol. Med. 5:235–238 [Google Scholar]
- 11. Carrillo-Muñoz A. J., Tur C., Torres J. 1996. In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. J. Antimicrob. Chemother. 37:815–819 [DOI] [PubMed] [Google Scholar]
- 12. Clinical and Laboratory Standards Institute 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed., M38-A CLSI, Wayne, PA [Google Scholar]
- 13. Drouhet E., Dupont B. 1992. In vitro antifungal activity of sertaconazole. Arzneimittelforschung 42:705–710 [PubMed] [Google Scholar]
- 14. Fernandez-Torres B., et al. 2001. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob. Agents Chemother. 45:2524–2528 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Grau M. T., Romero A., Sacristan A., Ortiz J. A. 1992. Dermal tolerance and phototoxicity studies of sertaconazole. Arzneimittelforschung 42:746–747 [PubMed] [Google Scholar]
- 16. Lewis J. S., II, Graybill J. R. 2008. Fungicidal versus fungistatic: what's in a word? Expert Opin. Pharmacother. 9:927–935 [DOI] [PubMed] [Google Scholar]
- 17. Martin-Mazuelos E., Aller A. I., Morilla D., Montero O. 1996. Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp. Chemotherapy 42:112–117 [DOI] [PubMed] [Google Scholar]
- 18. Palacin C., Sacristan A., Ortiz J. A. 1992. In vitro activity of sertaconazole. Arzneimittelforschung 42:699–705 [PubMed] [Google Scholar]
- 19. Palacin C., Sacristan A., Ortiz J. A. 1992. In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. Arzneimittelforschung 42:711–714 [PubMed] [Google Scholar]
- 20. Palacin C., Tarrago C., Agut J., Guglietta A. 2001. In vitro activity of sertaconazole, fluconazole, ketoconazole, fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeast isolates. Methods Find. Exp. Clin. Pharmacol. 23:61–64 [DOI] [PubMed] [Google Scholar]
- 21. Panackal A. A., Halpern E. F., Watson A. J. 2009. Cutaneous fungal infections in the United States: analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995–2004. Int. J. Dermatol. 48:704–712 [DOI] [PubMed] [Google Scholar]
- 22. Pfaller M. A., Sheehan D. J., Rex J. H. 2004. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17:268–280 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Robbins C. M., Elewski B. E. 16 December 2009, posting date Tinea pedis. eMedicine. http://reference.medscape.com/article/1091684
- 24. Savin R., Jorizzo J. 2006. The safety and efficacy of sertaconazole nitrate cream 2% for tinea pedis. Cutis 78:268–274 [PubMed] [Google Scholar]
- 25. Susilo R., Korting H. C., Strauss U. P., and Sertaconazole Study Group 2003. Dermatomycoses of the glabrous skin: a double-blind, randomised, comparative trial of sertaconazole 2% cream once daily versus vehicle. Clin. Drug Invest. 23:387–394 [DOI] [PubMed] [Google Scholar]
- 26. Weitzman I., Summerbell R. C. 1995. The dermatophytes. Clin. Microbiol. Rev. 8:240–259 [DOI] [PMC free article] [PubMed] [Google Scholar]